麻豆传媒

First positive phase III study for a GLP-1 agonist in chronic liver disease

Notably, tapering reduced the risk of infection compared with a fixed dose

A greater proportion of women on the waitlist and undergoing transplant since adoption

78% of patients in prospective study had tumor downstaging with immune checkpoint inhibitors

Improved markers of disease severity as well in small trial of steroid-ineligible patients

Seladelpar also improved markers of disease activity versus placebo

At highest dose, thyroid hormone receptor-beta agonist decreased liver fat content by 45%

1-year survival reached 78% for patients who received an emergency transplant

In randomized trial, oral elafibranor induced biochemical response at 1 year in 51% of patients

Results highlight the importance of prompt recognition and treatment of acute kidney injury

AASLD president: "No way we are going to be able to transplant our way out of this"

Latest REGENERATE analysis comes on heels of REVERSE flop

Plus: Normothermic machine perfusion for liver transplants and Noom Weight for NASH

With 10% efficacy at 6 months post-treatment, a finite HBV treatment may be on the horizon